The integrity of the American healthcare system relies on a fundamental principle: honesty. When private corporations partner with the federal government to provide care for the nation’s most vulnerable populations—seniors and those with disabilities—the trust placed in those entities is immense. However, that trust was recently tested as the U.S. Department of Justice (DOJ) announced a major settlement with Aetna Inc., one of the country’s largest health insurance providers.
In United States ex rel. Mary Melette Thomas v. Aetna Inc., et. al., No. 24-cv-339 (E.D. Pa. 2026) Aetna has agreed to pay $117.7 million to resolve allegations that it violated the False Claims Act (FCA) by submitting or failing to withdraw inaccurate diagnosis codes for its Medicare Advantage (MA) plan enrollees. This settlement is not just a financial penalty; it is a stark reminder of the ongoing “upcoding” epidemic and the government’s intensifying scrutiny of the Medicare Advantage program.
The Mechanics of the Allegations: How “Risk Adjustment” Was Manipulated
To understand why Aetna is paying nearly $118 million, one must understand how Medicare Advantage operates. Unlike traditional Medicare, where the government pays providers directly for services rendered, Medicare Advantage (Medicare Part C) involves the government paying private insurers, known as Medicare Advantage Organizations (MAOs), a fixed monthly amount per beneficiary.
To ensure that insurers are fairly compensated for taking on sicker patients, the Centers for Medicare & Medicaid Services (CMS) uses a “risk adjustment” model. Under this model, CMS pays MAOs more for beneficiaries with serious or chronic health conditions (who are expected to incur higher costs) and less for healthier individuals. These payments are based on medical diagnosis codes submitted by the insurers.
The government’s allegations against Aetna center on two distinct patterns of behavior:
-
The “Chart Review” Program (The $106.2 Million Portion)
The largest chunk of the settlement—approximately $106.2 million—stems from a “chart review” program Aetna operated for payment year 2015. Aetna hired professional diagnosis coders to review medical records (or “charts”) to identify any medical conditions that had not been previously reported.
While identifying missing codes is a legitimate practice, the DOJ alleged that Aetna used this program as a one-way street. When the coders found new diagnoses that would increase government payments, Aetna submitted them. However, when those same reviews revealed that previously submitted diagnosis codes were not substantiated by the medical record, Aetna allegedly failed to delete or withdraw those codes. By keeping unsupported codes on the books, Aetna avoided having to reimburse the government for overpayments, effectively “gaming” the system to maximize revenue while ignoring data that would decrease it.
-
The Morbid Obesity Coding (The $11.5 Million Portion)
The remaining $11.5 million of the settlement resolves allegations spanning from 2018 to 2023. During this period, the government claims Aetna knowingly submitted or failed to correct diagnosis codes for morbid obesity. In many cases, these diagnoses were allegedly inconsistent with the patients’ recorded Body Mass Index (BMI). Since morbid obesity is a high-risk condition that triggers significantly higher payments from CMS, submitting these codes without clinical support resulted in a substantial windfall of taxpayer funds.
The Power of the Whistleblower: Qui Tam and Accountability
This case highlights the critical role of whistleblowers in safeguarding public funds. The portion of the settlement involving morbid obesity began as a qui tam (whistleblower) lawsuit filed by Mary Melette Thomas, a former Aetna risk-adjustment coding auditor.
Under the False Claims Act, private individuals with knowledge of fraud against the government can file a lawsuit on the government’s behalf. If the case is successful, the whistleblower is entitled to a percentage of the recovery. In this instance, Ms. Thomas is set to receive approximately $2,012,500 for her role in bringing the alleged misconduct to light. This mechanism is often the only way the government can peer behind the corporate veil of massive insurance companies to identify systematic “upcoding.”
A “No-Win” for Transparency: Aetna’s Response and the OIG’s Warning
Despite the massive payout, Aetna has not admitted liability. A spokesperson for the company stated that they continue to disagree with the DOJ’s “industry-wide allegations” and settled merely to “avoid the uncertainty and further expense of prolonged litigation.”
However, the Department of Health and Human Services Office of Inspector General (HHS-OIG) took an unusually firm stance following the settlement. In a notable development, Aetna reportedly refused to enter into a Corporate Integrity Agreement (CIA). A CIA is a standard compliance-related oversight document that typically accompanies such settlements, requiring the company to implement rigorous internal monitoring for several years.
Because Aetna refused these integrity obligations, the HHS-OIG has reserved the right to exclude Aetna from federal healthcare programs in the future and has placed the company under “heightened scrutiny.” Acting Deputy Inspector General Scott J. Lampert was blunt: “Medicare Advantage relies on accurate reporting and attempts to manipulate the system undermine both the program’s integrity and the beneficiaries it serves. No company is beyond accountability, no matter how large or well known.”
The Broader Context: A Crackdown on Medicare Advantage
Aetna is not alone in the crosshairs. This settlement arrives amidst a massive federal “blitz” on Medicare Advantage fraud. With the government now paying private insurers over $500 billion annually to manage Medicare benefits, the financial stakes for taxpayers have never been higher.
Recent months have seen similar high-profile actions:
- Kaiser Permanente reached a record $556 million settlement in January 2026.
- Elevance Health has faced ongoing threats of enrollment sanctions.
- The DOJ has signaled that “risk adjustment fraud” is a top priority, as it accounts for billions of dollars in potentially improper payments every year.
What This Means for the Healthcare Industry and Consumers
For the healthcare industry, the message is clear: “Blind eye” auditing is a thing of the past. If an insurer conducts a medical record review, they must act on all the findings—both the ones that increase revenue and the ones that decrease it. Using data selectively to inflate risk scores is now a direct ticket to a False Claims Act investigation.
For Medicare beneficiaries, these settlements are a double-edged sword. On one hand, they ensure that the billions of dollars allocated for their care are actually being used for that purpose, rather than being diverted into corporate profits through fraudulent coding. On the other hand, the sheer scale of the fraud allegations across the industry raises concerns about the stability and transparency of the private plans millions of Americans rely on.
Final Thoughts
The $117.7 million Aetna settlement is a milestone in the fight against healthcare fraud, but it is likely just the beginning. As the government refines its data analytics and more whistleblowers come forward, the era of “easy money” through inflated risk adjustment in Medicare Advantage is coming to a close.
Transparency is no longer an option for health insurers; it is a requirement for survival. As U.S. Attorney David Metcalf of the Eastern District of Pennsylvania stated, “Those who seek to exploit Medicare Advantage should expect to be identified and held responsible.” For Aetna and its peers, the road ahead will involve significantly more oversight, whether they agree to it voluntarily or not.